Crystalloid

PreclinicalSmall molecule

KKonkuk University Medical Center

Crystalloid is one of 89 small molecule programs targeting Kidney Injury. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney InjuryActive, not recruiting

Acute Kidney InjuryActive, not recruiting

HemodynamicCompleted

HypotensionActive, not recruiting

Kidney InjuryPreclinical

Active, not recruiting

Acute Kidney InjuryPreclinical

Active, not recruiting

HemodynamicPreclinical

Completed

HypotensionPreclinical

Active, not recruiting

Competition

Competitive Landscape

90 competitors in Acute Kidney Injury

#DrugCompanyPhaseTrials

Letairis

Gilead

Approved

—2

Levophed

GGeneral Hospital of Ningxia Medical University

Approved

3 3

Glypressin

MMallinckrodt

Approved

2 4

Osmitrol

BB. Braun Medical Inc.

Approved

—5

Giapreza

LLa Jolla Pharmaceutical Company

Phase 3

2 6

Oraverse

LLife Extension Foundation Inc.

Phase 3

1 7

Northera

Lundbeck

Phase 2

1 8

Lamisil

Novartis

Phase 2

1 9

Pitressin

AAultman Health Foundation

Phase 2

1 10

Arginine Vasopressin

SStanford University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 2Not yet recruiting

Autoimmune Pulmonary Alveolar Proteinosis

NCT07890649

Clinical

Trials by Indication[1]

Fluid Resuscitation4 trials

Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity

Completed·KKonkuk University Medical Center·N/A·NCT02700607·40 enrolled

Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity for CABG Surgery

Unknown status·KKonkuk University Medical Center·N/A·NCT02757027·30 enrolled

Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity for Cardiac Surgery

Unknown status·KKonkuk University Medical Center·N/A·NCT02757118·30 enrolled

Show 1 more trial

Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity for Colon Surgery

Unknown status·KKonkuk University Medical Center·N/A·NCT02770027·30 enrolled

Hypotension2 trials

The Impact of Early Norepinephrine Administration on Outcomes of Patients With Sepsis-induced Hypotension

Completed·TTanta University·N/A·NCT05774054·64 enrolled

Comparison of Hydroxyethyl Starch and Crystalloid Coload Combined With Norepinephrine Infusion for Hypotension

Completed·GGeneral Hospital of Ningxia Medical University·N/A·NCT05475990·80 enrolled

Kidney Injury1 trial

The Effect of the Hydroxyethyl Starch on Kidney Injury in Pediatric Cardiac Surgery

Completed·SSeoul National University Hospital·N/A·NCT02599155·200 enrolled

Postoperative Morbidity1 trial

Effect of Goal-directed Crystalloid Versus Colloid Administration on Major Postoperative Morbidity

Completed·TThe Cleveland Clinic·N/A·NCT01195883·1,102 enrolled

Intraoperative1 trial

Postoperative Replacement of Intraoperative Iron Losses

Completed·KKepler University Hospital·Phase 4·NCT03680456·134 enrolled

6 more indications

Acute Kidney Injury1 trial

HES and Acute Kidney Injury in Adult Cardiac Surgery

Completed·UUniversity of Liege··NCT02445820·697 enrolled

Acute Lymphoblastic Leukemia1 trial

The Effect of Crystalloids and Colloids on Visceral Blood Flow

Completed·UUniversity of Nottingham·Phase 1/2·NCT01087853·25 enrolled

Hemodynamic1 trial

Fluid Investigation Colloid vs Crystalloid Reg. Renal Hemodynamics and Function

Completed·SSahlgrenska University Hospital·N/A·NCT01729364·30 enrolled

Hyperglycemia1 trial

Prevention and Treatment of Common Hyperglycemia in Surgery Pilot

Completed·UUniversity of Washington·Phase 4·NCT06624956·106 enrolled

Microcirculation1 trial

Effect of Different Strategies for Titrating a High MAP on Microcirculation

Completed·SSoutheast University, China·Phase 4·NCT02085291·24 enrolled

Autoimmune Pulmonary Alveolar Proteinosis1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIb Clinical Trial to Evaluate the Efficacy and Safety of Human Bone Marrow-Derived Mesenchymal Stem Cell (hBMMSC) Injection in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Not yet recruiting·JJiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.·Phase 2·NCT07890649·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Crystalloid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Crystalloid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Crystalloid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Konkuk University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKonkuk University Medical Center

Crystalloid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Fluid Resuscitation4 trials

Hypotension2 trials

Kidney Injury1 trial

Postoperative Morbidity1 trial

Intraoperative1 trial

Acute Kidney Injury1 trial

Acute Lymphoblastic Leukemia1 trial

Hemodynamic1 trial

Hyperglycemia1 trial

Microcirculation1 trial

Autoimmune Pulmonary Alveolar Proteinosis1 trial

References

Drug Info

Quick Facts

Related News